Table 2 Uveitis flares before and during each kind of anti‐tumour necrosis factor (TNF) treatment (n = 46 patients), in patients with spondylarthropathy: comparison between uveitis flares during the treatment with those during treatment with anti‐TNF antibody and soluble TNF receptor.
| Anti‐TNF (n = patients) | Period before anti‐TNF treatment | Period during anti‐TNF treatment | p Value* | ||||
|---|---|---|---|---|---|---|---|
| Duration of period (years) Mean (SD) | Number of uveitis flares/patient Mean (SD) | Number of uveitis flares/100 patient‐years Mean (SD) | Treatment period (years) Mean (SD) | Number of uveitis flares/patient Mean (SD) | Number of uveitis flares/100 patient‐years Mean (SD) | ||
| All anti‐TNF n = 46 | 15.2 (10.2) | 6.3 (9.7) | 51.8 (65.0) | 1.2 (1.1) | 0.2 (1.0) | 21.4 (74.9) | 0.03 |
| Soluble TNF receptor (etanercept) n = 13 | 11.5 (10.4) | 3.6 (4.1) | 54.6 (78.2) | 1.2 (1.1) | 0.5 (0.8) | 58.5 (121.9) | 0.92 |
| Anti‐TNF antibodies (adalimumab and infliximab) n = 33 | 16.7 (9.8) | 7.3 (11.1) | 50.6 (61.0) | 1.2 (1.1) | 0.1 (1.0) | 6.8 (39.3) | 0.001 |
| Infliximab n = 25 | 16.8 (10.4) | 7.3 (12.1) | 47.4 (58.9) | 1.4 (1.3) | 0.2 (1.2) | 9.0 (45.2) | 0.008 |
| Adalimumab n = 8 | 16.2 (8.7) | 7.2 (7.8) | 60.5 (70.4) | 0.6 (0.2) | 0 | 0 | 0.04 |
TNF, tumour necrosis factor.
*p Value comparing the number of uveitis flares/100 patient‐years before and during the treatment. Each patient is his or her own control.